Balyasny Asset Management
NEUP

Balyasny Asset Management’s Neuphoria Therapeutics NEUP Stock Holding History

Balyasny Asset Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Buy
142,228
+45
+0% +$217 ﹤0.01% 2434
2026
Q1 		$579K Buy
+142,183
New +$601K ﹤0.01% 2308

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Balyasny Asset Management's NEUP Position: Q2 2026 in Review

Balyasny Asset Management increased its Neuphoria Therapeutics (NEUP) stake by 0.03% in Q2 2026, buying an estimated $217 and bringing the position to 142,228 shares worth $622K. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

Balyasny Asset Management first reported a position in NEUP in Q1 2026 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Balyasny Asset Management held 142,228 shares of Neuphoria Therapeutics worth $622K as of Q2 2026.
  • Balyasny Asset Management bought 45 Neuphoria Therapeutics shares in Q2 2026, an estimated $217.
  • Neuphoria Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2434 holding.
  • Balyasny Asset Management first reported a position in Neuphoria Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.